ArticleFrontiers in oncology2026
GLA is associated with ESCC progression and chemotherapy response via DNA damage repair-related pathways.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is a highly lethal malignancy frequently complicated by chemoresistance. α-Galactosidase A (GLA), a lysosomal hydrolase associated with poor prognosis in multiple cancers, has not been investigated in ESCC. Methods: Two independent ESCC datasets (GSE161533, GSE38129) were used to screen commonly upregulated genes, which were ranked by diagnostic performance and further validated in an integrated single-cell RNA-seq atlas and an independent dataset (GSE20347), identifying GLA. GLA expression was validated by immunohistochemistry, qRT-PCR, and Western blot. Its biological function was assessed by siRNA-mediated knockdown combined with CCK-8, EdU, colony formation, Transwell, and wound healing assays. KEGG, GO, and GSEA were performed to explore underlying mechanisms. The effect of GLA knockdown on chemosensitivity, and the combination of the GLA pharmacological chaperone Migalastat with gemcitabine or cisplatin, were evaluated by CCK-8 assays in two ESCC cell lines. Results: GLA was significantly upregulated in ESCC, showed strong diagnostic performance across datasets, and was specifically enriched in malignant epithelial cells at the single-cell level. Multiple validation approaches confirmed GLA overexpression in ESCC cell lines and patient tissues. GLA knockdown markedly suppressed proliferation, colony formation, and migration. Enrichment analyses suggested that high GLA expression was associated with DNA damage repair, cell cycle, and DNA replication-related transcriptional programs, as well as with gemcitabine/cisplatin resistance-related genes. GLA knockdown increased the sensitivity of ESCC cells to gemcitabine and cisplatin, and Migalastat combined with either agent enhanced cytotoxicity in two ESCC cell lines, with combination index analysis indicating synergy. Conclusion: GLA is a novel, upregulated gene in ESCC with diagnostic relevance and an oncogenic role, and is associated with DNA damage repair-related transcriptional programs and chemotherapy response. Combining Migalastat with chemotherapy may represent a candidate strategy that warrants further mechanistic and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.